JL
Jennifer Kayden Lee (EVP, Head of North America) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Rhythm Pharmaceuticals, Inc. (RYTM). The largest single filing was $8.9M of RYTM (75,834 sh × $117.38, as filed), executed Aug 13. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.9M
shares × price, as filed
Last traded
Aug 13
Filed Aug 14
Median ADV $88.9M across their filed names
Open performance→Volume by month
Buys $0
Sells $9.4M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
RYTM
Rhythm Pharmaceuticals, Inc.
RYTM · 0 buys · 5 sells
5 filings
Recent filings
RYTMSALE
Rhythm Pharmaceuticals, Inc.
View filing →
$8.9M75,834 sh × $117.38
Exec Aug 13
Filed Aug 14 · 7:04 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. View filing → $116K
2,035 sh × $57.22
Exec Feb 19 2025
Filed Feb 19 2025 · 5:30 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. View filing → $247K
4,189 sh across 2 lots
Exec Feb 10 2025
Filed Feb 11 2025 · 5:30 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. View filing → $104K
1,733 sh × $60.08
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET RYTMSALE Rhythm Pharmaceuticals, Inc. View filing → $4.4M
66,661 sh across 3 lots
Exec Nov 11 2024
Filed Nov 13 2024 · 5:30 PM ET